BioBeOne

What BioBeOne does

BioBeOne Inc. is a Tokyo-based, privately held company founded in 2018 (firmographic data also indicates 2017) by Yukio Kitai, operating with a team of 1-10 employees from its Akasaka, Minato-ku headquarters. The company operates the BB1 System (BioBeOne AI Partnering System), a self-serve, web-based platform that enables pharmaceutical and regenerative medicine organizations to register projects and receive automated partner matches across Japan and international markets. Core features include automatic project matching and notification, a proprietary internal messaging function with disclosure capabilities and sub-member collaboration, and an international partnering service accessible via bilingual (English/Japanese) UI at bb1.biobeone.com.

The BB1 System is monetized through a three-tier annual subscription model: a free Basic plan, a Business plan at US$100 (JPY 10,000) per year, and a Premium plan at US$300 (JPY 30,000) per year, differentiated by sub-member count, project registrations, storage, and outbound contact limits. The go-to-market is product-led growth with no sales intervention; users self-register and discover partners through the platform's matching engine. A launch campaign offering paid membership free of charge ran through March 31, 2023 to seed initial project registrations. The company targets two primary vertical segments, pharmaceutical companies and regenerative medicine companies, addressing their need to find licensing, development, and open-innovation partners.

BioBeOne is founder-controlled with no disclosed institutional investors, parent entities, funding rounds, or external equity partners, and reports no revenue, customers, partnerships, awards, or patents in the available source material. Strategic positioning emphasizes domain specialization in pharma and regenerative medicine as a differentiator against broader partnering or generic deal-sourcing platforms.

Name

BioBeOne

Legal name

BioBeOne Inc.

Website

https://biobeone.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

BioBeOne operates the BB1 System, a self-serve AI-branded partnering platform that automatically matches pharmaceutical and regenerative medicine organizations globally through tiered annual subscriptions.

Ownership category

akta.pro rank

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Premium Membership Plans: BioBeOne generates revenue through tiered annual subscription plans. The Basic plan is free, Business plan costs $100/year, and Premium plan costs $300/year. These plans provide increasing access to project registrations, sub-member functions, storage capacity, and contact limits.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

BioBeOne operates the BB1 System (BioBeOne AI Partnering System), a self-serve international web platform that helps pharmaceutical and regenerative medicine companies register projects and automatically get matched with potential business partners for drug development, licensing, and open innovation collaboration in Japan and worldwide. The platform supports team collaboration via sub-membership functions and a proprietary internal messaging system with project information disclosure.

Product overview

BioBeOne operates the BB1 System (BioBeOne AI Partnering System), a unified cloud-based partnering platform for the pharmaceuticals and regenerative medicine industries. The platform consists of a core system with tiered membership plans (Basic/Free, Business at $100/year, and Premium at $300/year) offering automated partner matching, internal messaging with disclosure functions, and international partnering services. Users can register projects and the AI-powered system automatically identifies and notifies them of matching business partners. The system serves as a global bridge for partnership and open innovation in drug development and regenerative medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• BB1 System (BioBeOne AI Partnering System) An international web-based partnering and open innovation platform that automatically finds business partners in pharmaceuticals and regenerative medicine in Japan and worldwide. The system enables organizations to register projects, receive AI-driven automated partner matches, communicate via proprietary internal messaging with project information disclosure, and collaborate through sub-membership team functions.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Citeline (Informa Pharma Intelligence): Citeline (formerly Pharma Intelligence/Informa) offers pipeline, deals, and partnering intelligence across the pharma and biotech industry. It serves pharma BD teams with comparable end-customer needs (finding partners, tracking deals) but as part of a much broader intelligence portfolio.
• Biomedtracker (Informa): Biomedtracker (Sparta Systems / Informa) tracks pharma R&D catalysts, deals, and partnering opportunities for biopharma business development. It overlaps with BioBeOne's target customers (pharma BD teams) and use cases (partner identification, deal tracking) but offers deeper R&D analytics.
• BioCentury: BioCentury is an established life-science intelligence and partnering media brand serving biopharma executives with deal coverage, partner discovery, and BCLSUMMIT-style structured partnering events. Comparable to BioBeOne in serving the pharma BD workflow but with a much broader media and intelligence portfolio.
• GlobalData Pharmaceutical Intelligence: GlobalData provides pharma intelligence, deal databases, and company profiles for industry BD teams. While not a pure partnering marketplace, it serves overlapping customer needs (partner discovery, market mapping) with a much larger data and intelligence footprint.
• EBD Group / partneringONE: EBD Group's partneringONE is the dominant pharma partnering platform used at BIO Convention, BIO Europe, and other major industry events. It serves the same pharma/regen medicine partnering use case as BioBeOne but is embedded in the event ecosystem and has established enterprise adoption across global pharma.

Direct peers

• Inpart: Inpart (formerly Known Medicine) operates a SaaS partnering platform that connects life-science innovators with industry partners for licensing, collaboration, and technology transfer. Like BioBeOne, it focuses on scientific/therapeutic partnering workflows with structured project profiles and partner matching.
• DealForma: DealForma provides a deal-making and partnering intelligence platform for biopharma business development teams. It targets the same pharma BD/Licensing workflow as BioBeOne, with structured project data and partner discovery functionality.
• PartneringPlace: PartneringPlace is a structured pharma partnering platform enabling companies to showcase projects and find partners outside of physical conferences. It directly competes with BioBeOne's core use case of automated partner discovery for pharma and biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioBeOne